Roivant Sciences Ltd. (NASDAQ:ROIV) Receives Consensus Rating of “Moderate Buy” from Brokerages

Roivant Sciences Ltd. (NASDAQ:ROIV) has been given an average rating of “Moderate Buy” by the ten ratings firms that are covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a hold rating and nine have given a buy rating to the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $16.90.

Several equities analysts recently commented on the stock. Wolfe Research assumed coverage on shares of Roivant Sciences in a research report on Thursday, February 15th. They issued an “outperform” rating and a $17.00 price objective for the company. The Goldman Sachs Group raised their price target on shares of Roivant Sciences from $16.00 to $18.00 and gave the stock a “buy” rating in a research report on Wednesday, April 3rd. TheStreet raised shares of Roivant Sciences from a “d” rating to a “c+” rating in a research report on Tuesday, February 13th. HC Wainwright reissued a “buy” rating and set a $18.00 price target on shares of Roivant Sciences in a research report on Monday, April 22nd. Finally, Truist Financial reissued a “buy” rating and set a $23.00 price target on shares of Roivant Sciences in a research report on Monday, March 25th.

Insider Activity at Roivant Sciences

In related news, COO Eric Venker sold 96,950 shares of Roivant Sciences stock in a transaction on Friday, February 9th. The shares were sold at an average price of $10.92, for a total value of $1,058,694.00. Following the sale, the chief operating officer now owns 532,207 shares of the company’s stock, valued at approximately $5,811,700.44. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 4.60% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ROIV. GSA Capital Partners LLP purchased a new position in shares of Roivant Sciences during the 1st quarter worth $527,000. Mutual of America Capital Management LLC raised its holdings in shares of Roivant Sciences by 116.8% during the 1st quarter. Mutual of America Capital Management LLC now owns 325,937 shares of the company’s stock worth $3,435,000 after acquiring an additional 175,574 shares during the period. Fifth Lane Capital LP purchased a new position in shares of Roivant Sciences during the 1st quarter worth $211,000. Nordea Investment Management AB purchased a new position in shares of Roivant Sciences during the 1st quarter worth $2,851,000. Finally, Hussman Strategic Advisors Inc. purchased a new position in shares of Roivant Sciences during the 1st quarter worth $1,107,000. Hedge funds and other institutional investors own 64.76% of the company’s stock.

Roivant Sciences Stock Up 1.3 %

Shares of Roivant Sciences stock opened at $11.39 on Friday. The company has a debt-to-equity ratio of 0.06, a current ratio of 27.79 and a quick ratio of 27.79. Roivant Sciences has a 1 year low of $8.06 and a 1 year high of $13.24. The firm’s 50-day moving average is $10.89 and its two-hundred day moving average is $10.40. The stock has a market cap of $9.18 billion, a price-to-earnings ratio of 2.19 and a beta of 1.30.

Roivant Sciences (NASDAQ:ROIV) last released its quarterly earnings results on Tuesday, February 13th. The company reported ($0.26) EPS for the quarter, beating the consensus estimate of ($0.33) by $0.07. The business had revenue of $37.14 million during the quarter, compared to analyst estimates of $30.72 million. Roivant Sciences had a net margin of 3,624.14% and a negative return on equity of 33.38%. As a group, research analysts expect that Roivant Sciences will post -1.36 earnings per share for the current fiscal year.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.